Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.74 |
| ▸ | ACHE | P22303 | 14/20 | 0.66 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19400357 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL1077924 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL19400387 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL19400416 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL3629434 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL19400363 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL3625938 | 0.98 | EPHX2 (0.76) | EPHX2ACHEPLA2G2A | |
| SCHEMBL9832210 | 0.95 | EPHX2 (0.81) | EPHX2ACHEPLA2G2A | |
| SCHEMBL480293 | 0.95 | ACHE (0.68) | EPHX2ACHE | |
| SCHEMBL8920145 | 0.93 | EPHX2 (0.84) | EPHX2ACHEPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2091909-A1 | WATER-SOLUBLE PRODRUGS OF FLORFENICOL AND ITS ANALOGS | Schering-Plough Ltd. (CH) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008076259-A1 | WATER-SOLUBLE PRODRUGS OF FLORFENICOL AND ITS ANALOGS | SCHERING-PLOUGH LTD. (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-1735285-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005095348-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6858744-B2 | Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003093247-A2 | ANTIBACTERIAL AGENTS | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2003-11-13 | — | — | WO | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | EPHX2 4515/4885ACHE 4751/4885PLA2G2A 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.